We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
-1.39%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33.8M
Cap. Flow
% of AUM
9.8%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$4.2M |
| 2 |
Procter & Gamble
PG
|
+$3.18M |
| 3 |
Apple
AAPL
|
+$2.96M |
| 4 |
Booking.com
BKNG
|
+$2.81M |
| 5 |
Diageo
DEO
|
+$2.76M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TSMC
TSM
|
+$3.37M |
| 2 |
NVIDIA
NVDA
|
+$3.35M |
| 3 |
On Holding
ONON
|
+$2.92M |
| 4 |
Carnival Corporation Ltd
CCL
|
+$2.64M |
| 5 |
ASML
ASML
|
+$2.21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EQRX
276
DELISTED
EQRx, Inc. Common Stock
EQRX
| $27.8K | 0.01% |
12,513
+6,125
| +96% | +$13.1K |
|
|
DAWN
277
DELISTED
Day One Biopharmaceuticals
DAWN
| $27.3K | 0.01% |
2,226
+1,262
| +131% | +$16.5K |
|
278
Arvinas
ARVN
$580M
| $27K | 0.01% |
1,374
+674
| +96% | +$16.5K |
|
279
Pliant Therapeutics
PLRX
$66.3M
| $26.5K | 0.01% |
1,529
+754
| +97% | +$13.1K |
|
280
Ligand Pharmaceuticals
LGND
$5.85B
| $26.4K | 0.01% |
441
+215
| +95% | +$14.2K |
|
281
Relay Therapeutics
RLAY
$4.4B
| $26.4K | 0.01% |
3,135
+1,541
| +97% | +$16.6K |
|
282
Syndax Pharmaceuticals
SNDX
$1.77B
| $25.9K | 0.01% |
1,782
+880
| +98% | +$16.6K |
|
283
Replimune Group
REPL
$1.43B
| $25.8K | 0.01% |
1,509
+752
| +99% | +$14.8K |
|
|
RVNC
284
DELISTED
Revance Therapeutics, Inc.
RVNC
| $25.8K | 0.01% |
2,250
+1,148
| +104% | +$22.1K |
|
|
DCPH
285
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $25.8K | 0.01% |
2,026
+997
| +97% | +$13.8K |
|
286
Tango Therapeutics
TNGX
$4.31B
| $25.5K | 0.01% |
2,263
+1,105
| +95% | +$6.74K |
|
287
Protagonist Therapeutics
PTGX
$9.84B
| $24.6K | 0.01% |
1,473
+723
| +96% | +$14K |
|
288
Keros Therapeutics
KROS
$222M
| $24.2K | 0.01% |
758
+370
| +95% | +$13.8K |
|
|
AVDL
289
DELISTED
Avadel Pharmaceuticals
AVDL
| $23.7K | 0.01% |
2,298
+1,454
| +172% | +$19.5K |
|
290
Ardelyx
ARDX
$1.03B
| $22.8K | 0.01% |
5,592
+2,781
| +99% | +$10.8K |
|
|
VERV
291
DELISTED
Verve Therapeutics
VERV
| $21.8K | 0.01% |
1,641
+829
| +102% | +$13.3K |
|
292
Innoviva
INVA
$1.5B
| $21.7K | 0.01% |
1,674
+816
| +95% | +$10.6K |
|
293
Cogent Biosciences
COGT
$6.76B
| $21.3K | 0.01% |
2,189
+1,259
| +135% | +$14.9K |
|
294
ADMA Biologics
ADMA
$2.19B
| $20.6K | 0.01% |
5,764
+2,851
| +98% | +$11K |
|
|
INBX
295
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $20.5K | 0.01% |
1,117
+545
| +95% | +$11.4K |
|
296
Adaptive Biotechnologies
ADPT
$4.02B
| $20.3K | 0.01% |
3,719
+1,828
| +97% | +$12.1K |
|
297
Collegium Pharmaceutical
COLL
$834M
| $20.1K | 0.01% |
899
+445
| +98% | +$10.1K |
|
|
ICPT
298
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $19.9K | 0.01% |
1,071
+524
| +96% | +$5.93K |
|
299
ImmunityBio
IBRX
$8.2B
| $19.8K | 0.01% |
11,702
+5,987
| +105% | +$12K |
|
300
Kymera Therapeutics
KYMR
$9.48B
| $19.8K | 0.01% |
1,421
+696
| +96% | +$14K |
|
Similar funds
HA
JPM
CPO
GWM
JIP
RMC
GACM
RIA
China Universal Asset Management Company's Q3 2023 Portfolio in Review
As of Q3 2023, China Universal Asset Management Company held 466 positions worth $345M, up 6.5% from $324M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
China Universal Asset Management Company deployed $33.8M of net new capital in Q3 2023, opening 14 new positions and adding to 365 existing holdings. Its largest new stake was SPDR Gold MiniShares Trust: 71,700 shares worth $2.63M.
By sector, the portfolio is most concentrated in Technology at 38% of assets, down from 42% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was TSMC, an estimated $3.37M trimmed.
- China Universal Asset Management Company's largest Q3 2023 buy was SPDR Gold MiniShares Trust: 71,700 shares worth $2.63M.
- China Universal Asset Management Company added most to Amazon in Q3 2023, an estimated $4.2M increase.
- China Universal Asset Management Company's biggest Q3 2023 reduction was TSMC, cutting an estimated $3.37M.
- China Universal Asset Management Company fully exited Carnival Corporation Ltd in Q3 2023, selling an estimated $2.64M.
- China Universal Asset Management Company's ten largest holdings make up 33% of its $345M portfolio in Q3 2023.
- China Universal Asset Management Company opened 14 new positions and closed 20 in Q3 2023.
- China Universal Asset Management Company's portfolio value rose 6.5% quarter-over-quarter to $345M.
Based on China Universal Asset Management Company's 13F filing for Q3 2023, filed 31 Oct 2023.